PAX-8 is expressed in the thyroid (and associated carcinomas), non-ciliated mucosal cells of the fallopian tubes and simple ovarian inclusion cysts, but not normal ovarian surface epithelial cells. PAX-8 is expressed in a high percentage of ovarian serous, endometrioid, and clear cell carcinomas, but only rarely in
primary ovarian mucinous adenocarcinomas. Studies have also found PAX-8 experession in renal tubules as well
as renal carcinoma, nephroblastoma and seminoma. Over 98% of clear cell RCCs, 90% of papillary RCCs, and
95% of oncocytomas were positive for PAX-8, frequencies which are similar or better than for PAX-2. Similarly, the absence of expression of PAX-8 in breast and other non-GYN carcinomas other than those primary to the thyroid indicates that PAX-8 is an important new marker of ovarian cancer and a useful marker for the differential
diagnoses in lung and neck tumors, or tumors at distant sites where primary lung carcinoma or thyroid carcinoma are possibilities. PAX-8, combined with organ system-specific markers such as uroplakin, mammaglobin, and TTF-1 can be a very useful panel to determine the primary site of invasive micropapillary carcinomas of ovary from bladder, lung, and breast. Unlike the polyclonal anti-PAX-8 antibody, the ZR1 rabbit monoclonal antibody does not react with pancreatic neuroendocrine tumors and thymic tumors.


  • Source
    Rabbit Monoclonal
  • Clone
  • Class
  • Isotype
    Rabbit IgG
  • Tested Reactivity
  • Localization
  • Positive Control
    Ca Thyroid, Ovarian serous Ca

Ordering Information

  • Catalog
    Pack Size
  • PR114-3ml
    3 ml(RTU)
  • PR114-6ml
    6 ml(RTU)
  • HAR114-3ml
    3 ml(RTU)
  • HAR114-6ml
    6 ml(RTU)